SUBSCRIBE
SUBSCRIBE
News   Drug Development

ZIOPHARM, Inc. Commences Treatment of First Patients in Two Separate Phase I/II Combination Studies of Both Indibulin and Palifosfamide

February 4, 2008 | 
1 min read
NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), announced today that dosing of the first patient took place in two separate new studies, including:
Clinical research Phase I
MORE ON THIS TOPIC
Painful female periods concept. Vector flat character illustration. Woman standing and suffering menstrual abdominal pain isolated on pink background. Design for health care.
Women’s Health
Organon’s Endometriosis Drug Discontinued After Failing To Improve Pain
July 2, 2025
 · 
1 min read
 · 
Annalee Armstrong
IN PARTNERSHIP WITH IQVIA
Understanding the FDA’s AI Guidance in Pharmacovigilance
July 1, 2025
 · 
1 min read
 · 
Lori Ellis
Hand holding a nasal spray bottle against a white background
Psychedelics
Beckley’s Psychedelic Nasal Spray Clears Phase II Depression Study
July 1, 2025
 · 
2 min read
 · 
Tristan Manalac
Collage with halftone hands putting puzzle together. Teamwork concept vector pop art retro style illustration. Partnership and relationship design element for infographic, poster, website
Rare diseases
FDA Signs Off on Neurogene’s ‘Best-Case Scenario’ Pivotal Study Design for Rett Syndrome
July 1, 2025
 · 
2 min read
 · 
Tristan Manalac